Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

BACKGROUND: Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19). One of the Study 19 inclusion criteria was forced vital capacity (FVC) ≥80% of predicted (≥80%p). Therefore, the study provided no information on ed...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Benjamin Rix, Heiman-Patterson, Terry, Wiedau-Pazos, Martina, Liu, Shawn, Zhang, Jeffrey, Apple, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197041/
https://www.ncbi.nlm.nih.gov/pubmed/35700157
http://dx.doi.org/10.1371/journal.pone.0258614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197041/
https://www.ncbi.nlm.nih.gov/pubmed/35700157
http://dx.doi.org/10.1371/journal.pone.0258614

Ejemplares similares